Here are the 10-Q quarterly reports from Vyome Holdings, Inc. (HIND) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow HIND and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HIND filings page.
Vyome Holdings, Inc. (HIND) is a clinical-stage specialty pharmaceutical company focused on immune‑inflammatory and rare diseases, reporting two segments: a small India-based pharmaceutical revenue stream and a larger biotechnology R&D operation. For the six months ended June 30, 2026, revenue was $58,546, down from $248,535 in 2025, generating gross profit of $28,303.
Operating expenses rose sharply to $2,020,809, driven by research and development of $1,173,128 and selling, general and administrative expenses of $842,466. The company recorded other income, net, of $287,302, mainly interest income, resulting in a net loss of $1,705,204 versus $602,732 a year earlier. Operating cash outflow was $2,339,676.
Cash and cash equivalents increased to $7,887,510 from $4,982,333, primarily from an at‑the‑market equity program that raised $5,285,868. There is no debt outstanding; total liabilities were $1,864,656 and stockholders’ equity was $7,311,706, with 7,018,528 common shares outstanding. The pipeline includes lead asset VT‑1953 for malignant fungating wounds (Phase II completed, orphan drug designation application filed and FDA pre‑IND feedback received), a Phase III‑ready acne program VB 1953, and newly in‑licensed JAK inhibitor assets. Vyome also disclosed an Indian GST tax refund dispute with a potential demand of about $750,000, which it is contesting and for which no liability has been recorded. Management believes current resources and an equity facility can fund operations for at least 12 months while it continues to seek additional financing.
Vyome Holdings, Inc. reports results for the three months ended March 31, 2026, showing a small revenue base and higher investment in R&D. Revenue was $31,591, down from $198,581 a year earlier, entirely from its Indian dermatology products and royalties.
The company recorded a net loss of $985,521, compared with $293,974 in the prior-year quarter, driven mainly by increased research and development expense of $666,405 and selling, general and administrative costs of $477,575. Operating cash outflow was $1,435,964.
Liquidity improved after an at-the-market equity program, which raised $5,288,868 of gross proceeds, lifting cash and cash equivalents to $8,795,783 at March 31, 2026. Common shares outstanding rose to 7,018,528. Vyome remains a clinical-stage company focused on immune-inflammatory and rare disease programs, including lead topical candidate VT-1953.